Seroconversion Analysis After Habitual Hepatitis B Vaccination Scheme in Patients With Inflammatory Bowel Diseases

Cunha, Isabella de Souza; Silva, Tayná Cristina da; Malluta, Éverson Fernando; Scolaro, Bruno Lorenzo; Velho, Pablo Sebastian; Stall, Juliane

doi:10.1590/s0004-2803.202000000-12

Cited by 3 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, a total of 1005 articles were screened for titles and abstracts and eventually 36 articles underwent full‐text screening ( Figure 1 ) . After reviewing the full texts, 21 studies were included for the analysis 7,17–36 . Details of excluded studies are provided in Table S2 37–51 .…”

Section: Resultsmentioning

confidence: 99%

“…Details of excluded studies are provided in Table S2 37–51 . Of the included studies, 17 were full articles 7,17–26,29,31–35 and 4 were published as abstracts 27,28,29,31 . One included study was published in Spanish and translated to English 36 Table S3.…”

Section: Resultsmentioning

confidence: 99%

“…There were 21 studies which included 11 prospective studies 7,20,21,23–28,30,35 and 10 retrospective studies 17–19,22,29,31–34,36 . Prospective studies included two randomised controlled trials, 21,24 seven cohort studies 20,23,25–28,30 and two case–control studies 7,35 .…”

Section: Resultsmentioning

confidence: 99%

“…29 Standard doses of 10-20 μg (as recommended by manufacturer) were used for vaccination in 13 studies. 7,[17][18][19][20][22][23][24]28,31,33,35,36 Three studies used the double dose (40 μg) 26,27,30 and two studies compared the double dose with standard dose. 21,25 The exact dose of vaccine administered was not mentioned in three studies.…”

Section: Re Sultsmentioning

confidence: 99%

“…After reviewing the full texts, 21 studies were included for the analysis. 7,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] Details of excluded studies are provided in Table S2. [37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] Of the included studies, 17 were full F I G U R E 1 PRISMA flowchart showing the selection of studies for the systematic review articles 7,[17][18][19][20][21][22][23][24][25][26]29,[31][32]…”

Section: Re Sultsmentioning

confidence: 99%

See 4 more Smart Citations

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Singh

Jena

Mahajan

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background:The response rate of hepatitis B virus (HBV) vaccination in patients with inflammatory bowel disease (IBD) is variable. Increasing dose or accelerated schedule is the suggested strategy to improve seroconversion. Aim:We performed a meta-analysis to determine the pooled response rate of HBV vaccination and to identify the predictors of seroconversion. Methods:We searched PubMed, Embase and Cochrane library databases. Studies reporting the response of HBV vaccination in IBD patients were included. Response was recorded as adequate immune response (AIR, >10 IU/L) and Effective immune response (EIR, >100 IU/L). Pooled AIR and EIR rates were calculated for different doses (10-20 μg or 40 μg) and schedules (standard: 0, 1 and 6 months or accelerated: 0, 1 and 2 months). Meta-analysis was performed to identify the predictors of response.Results: Twenty-one studies including 2602 patients were eligible. Pooled AIR and EIR rates after HBV vaccination were 62% (95% CI, 55-68) and 42% (95% CI, 37-48), respectively. Pooled AIR and EIR rates for standard and double dose were similar.Pooled AIR and EIR rates were also comparable for different schedules of HBV vaccination. Gender, IBD subtype and disease activity did not affect the response rate.Use of immunosuppression [immunomodulators (RR: 0.73, 95% CI, 0.62-0.87) and anti-TNFs (RR: 0.72, 95% CI, 0.60-0.87)] was a predictor of poor immune response compared to no immunosuppressive therapy. Conclusion:Patients with IBD have a poor serological response after HBV vaccination. HBV screening and vaccination should preferably be done before starting the immunosuppressive drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Re Sultsmentioning

confidence: 99%

Section: Re Sultsmentioning

confidence: 99%

See 3 more Smart Citations

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Singh

Jena

Mahajan

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

Wellens

Colombel

Satsangi

et al. 2021

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Since the beginning of the pandemic, patients with inflammatory bowel diseases (IBD) have been considered at high-risk for infection and complications of COVID-19. However, IBD patients and patients taking immunosuppressive therapy were excluded from clinical phase III vaccine trials, complicating the assessment of effectiveness of these new vaccines. From past experience we know that adapted vaccination strategies may be appropriate in some IBD patients to optimize immunogenicity. We review current evidence on SARS-CoV-2 vaccination relevant to IBD patients, including immune responses from humoral to cellular, emerging data on new variants and off-label vaccination schemes. We also identify clinical and scientific knowledge gaps that can be translated into both large-scale population-based studies and targeted vaccine studies to describe the precise immune responses induced by SARS-CoV-2 vaccines in IBD patients. We strongly endorse the recommendation of vaccinating IBD patients to ensure maximal protection from COVID-19 both for the individual and the community.

show abstract

Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease patients are at risk of hepatitis B infection. Data on this prevalence from South Asia are limited. We conducted a prospective study comprising of 76 inflammatory bowel disease patients between October 2013 and August 2014. Prevalence of hepatitis B surface antigen in inflammatory bowel disease, ulcerative colitis and Crohn’s disease patients were 2.6%, 2.4% and 3% respectively and that of markers of hepatitis B exposure (hepatitis B surface antigen /hepatitis B core antibody) were 11.8%, 14.3% and 9.1% respectively. Risk factors found significantly more common in those positive for viral markers compared to those negative were age, non-inflammatory bowel disease related surgery and hospital admission. Only 7(9.2%) had completed hepatitis B vaccination. There is a need to create awareness among physicians regarding the importance of hepatitis B screening and vaccination in inflammatory bowel disease patients.

show abstract

Seroconversion Analysis After Habitual Hepatitis B Vaccination Scheme in Patients With Inflammatory Bowel Diseases

Cited by 3 publications

References 22 publications

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India

Contact Info

Product

Resources

About